VIEW THE LATEST NEWS ARTICLES … OR GO BACK TO THE ARCHIVES !

In 2nd-line treatment , after imatinib ( n = 266 evaluable ) a

Median duration of MCyR was not reached at the time of analysis

53 % of patients with MCyR maintained MCyR for at least 18 months ( with a minimum follow-up of 23 months )

In 3rd-line treatment , after imatinib followed by nilotinib and / or dasatinib therapy ( n = 108 evaluable )

• 27 % of patients achieved MCyR by 6 months ( 95 % CI : 18.8 , 36.2 )

• 32 % of patients achieved MCyR with a minimum follow-up of 13 months

• Median duration of MCyR was not reached at the time of analysis — 51 % of patients with MCyR maintained MCyR for at least 9 months ( with a minimum follow-up of 13 months )

Warnings and precautions include : gastrointestinal toxicity , myelosuppression , hepatic toxicity , fluid retention , renal toxicity , and embryofetal toxicity . Please see Important Safety Information below for more detail .

Most common adverse reactions observed in > 20 % of patients in the Phase 1 / 2 safety population ( N = 546 )

All grades (%) Diarrhea ( 82 ) Rash ( 35 )

Vomiting ( 39 ) Fatigue ( 24 ) Abdominal pain ( 37 )

For more information on BOSULIF , visit www . BosulifHCP . com .

Most common Grade 3 / 4 adverse reactions observed in ≥10 % of patients

Grade 3 / 4 (%) Thrombocytopenia ( 29 )

Anemia ( 13 ) Neutropenia ( 12 ) a

Median duration of treatment was 22 months for evaluable patients . MCyR = major cytogenetic response .

Embryofetal Toxicity : BOSULIF may cause fetal harm when administered to a pregnant woman . Women of childbearing potential should be advised of potential hazard to the fetus and to avoid becoming pregnant while receiving BOSULIF .

Adverse Reactions : The most common adverse reactions observed in greater than 20 % of patients in the Phase 1 / 2 safety population ( N = 546 ) were diarrhea , nausea , thrombocytopenia , vomiting , abdominal pain , rash , anemia , pyrexia , and fatigue . The most common Grade 3 / 4 adverse reactions and laboratory abnormalities observed in greater than 10 % of patients were thrombocytopenia , anemia , and neutropenia .

CYP3A Inhibitors and Inducers : Avoid concurrent use with strong or moderate CYP3A inhibitors or inducers .

Proton Pump Inhibitors : Consider using short-acting antacids or H2 blockers instead of PPIs to avoid a reduction in BOSULIF exposure . Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours .

Nursing Mothers : Given the potential for serious adverse reactions in nursing infants , a decision should be made whether to discontinue nursing or BOSULIF , taking into account the importance of the drug to the mother .

References : 1 . Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ®) for Chronic Myelogenous Leukemia V . 1.2016 . © National Comprehensive Cancer Network , Inc . 2015 . All rights reserved . Accessed October 27 , 2015 . To view the most recent and complete version of the guideline , go online to NCCN . org . NATIONAL COMPREHENSIVE CANCER NETWORK ®, NCCN ®, NCCN GUIDELINES ®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network , Inc . 2 . BOSULIF Prescribing Information . New York , NY : Pfizer Inc .

Please see brief summary of full Prescribing Information on the following pages .

PP-BOS-USA-0288-01 © 2016 Pfizer Inc . All rights reserved . July 2016